Latest News

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

The oral STAT6 degrader achieved deep STAT6 suppression, up to 63% EASI reduction, and gains in asthma and rhinitis scores by week 4.

Hurst discusses data showing durably raised protective AAT levels in patients with alpha-1 antitrypsin deficiency.

At ERS 2026, John Oppenheimer, MD, discusses how PERFORM supports earlier escalation in patients with uncontrolled, infrequently exacerbating asthma.

ADVANCE Outcomes at ERS 2026 demonstrated improved odds of improvement and reduced odds of worsening.

The oral RARβ/γ agonist improved FVC and reduced fibrotic biomarkers over 12 weeks in a phase 2a trial presented at the ERS Congress 2026.

A COPD genetic risk score was linked to reduced lung function growth from birth to age 6, but only in children with high air pollution exposure.

Novartis announced pelacarsen did not meet its primary endpoint in the phase 3 Lp(a)HORIZON cardiovascular outcomes trial despite Lp(a) lowering.

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Ross Levy, MD, explains why the LEADderm Skin Angels panel matters and what dermatology innovation looks like in daily practice.

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

Alpha-gal syndrome remains vastly underdiagnosed, with expanding tick geography and delayed reactions complicating recognition across specialties.

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

Hepatology in August 2026: FDA designations for volixibat and lonafarnib, ketogenic diet liver data, and alcohol use in CLD.

Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, break down CARDIO-TTRansform and the new 2026 ESC heart failure guidelines.

PAH specialists discuss sotatercept, risk-based escalation, and access barriers shaping pulmonary arterial hypertension care.

At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.

The FDA is expected to complete its review by late April 2027, based on positive phase 3 results from the TETON-1 and TETON-2 trials in IPF.

The ASPIRED trial found immediate ECG monitoring in the ED did not reduce recurrent syncope but doubled arrhythmia detection and cut mortality.

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8